Abstracts tagged "Comorbidity"

Abstract Number: 1394 • ACR Convergence 2025
Burden of Comorbidities Across EULAR Sjögren’s Syndrome Disease Activity Index (ESSDAI) Domains: Treatment Prevalence Among Commercially Insured Sjögren’s Patients in the United States
Minoti Ganguli, Annie Kilby, Ahva Shahabi and Tsu-Chieh Jay Lin, Amgen Inc., Thousand Oaks, CA
Background/Purpose: Sjögren’s disease (SjD) is a systemic disorder characterized by exocrine gland inflammation, leading to dry eyes/mouth, and multiple organ systems involvement1. The European League…
Abstract Number: 0215 • ACR Convergence 2025
Impact of Global Review on Comorbidity Management in Inflammatory Arthritis Patients
Alexandra Kobza¹, Camille Bourgeois², Olivier Fogel³, Maxime Dougados⁴ and Anna Molto⁵, ¹University of Calgary, North Vancouver, BC, Canada, ²Hospital general universitario Gregorio Marañon, Madrid, Madrid, Spain, ³AP-HP, Paris, France, ⁴Department of Medicine, Hopital Cochin, Universite de Paris, Paris, France, ⁵Assistance Publique Hôpitauxde Paris, Paris, France
Background/Purpose: Patients with inflammatory arthritis (IA), including rheumatoid arthritis (RA) and spondyloarthritis (SpA), face elevated risk for comorbidities that complicate disease management. Although rheumatology societies…
Abstract Number: 2079 • ACR Convergence 2025
Association Between Symptomatic Knee Osteoarthritis and Health-Related Quality of Life in Individuals with Type 2 Diabetes: A Cross-Sectional Study
Abdalmohsen Almodahka¹, Alanna Weisman², Baiju Shah³, Tristan Watson⁴, Ian stanaitis⁵, Amish Parikh⁶, Robert Goldberg⁶, Lorraine Lipscombe⁷, Gillian Hawker¹ and Lauren King¹, ¹University of Toronto, Toronto, ON, Canada, ²University Health Network Toronto General Hospital Site/Sinai Health System, Toronto, ON, Canada, ³Sunnybrook Health Sciences Centre, Toronto, ON, Canada, ⁴Institute of Health Policy, Management and Evaluation, Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada, ⁵Research and Innovation Institute, Women’s College Hospital, Toronto, ON, Canada, Toronto, ON, Canada, ⁶Division of Endocrinology, Department of Medicine, Trillium Health Partners, Mississauga, ON, Canada, Toronto, ON, Canada, ⁷Department of Medicine, University of Toronto, Research and Innovation Institute, Women’s College Hospital, Toronto, ON, Canada, Toronto, ON, Canada
Background/Purpose: Knee osteoarthritis (OA) and type 2 diabetes (T2D) commonly coexist, but their combined impact on health-related quality of life (HRQoL) remains understudied. Our objective…
Abstract Number: 1393 • ACR Convergence 2025
Prevalence of Sjögren’s Disease in the United States – A Retrospective Cohort Study Among a Commercially Insured Population (2019-2023)
Minoti Ganguli, Annie Kilby, Ahva Shahabi and Tsu-Chieh Jay Lin, Amgen Inc., Thousand Oaks, CA
Background/Purpose: Sjögren’s disease (SjD) is a systemic autoimmune condition characterized by diverse clinical manifestations, which often complicates diagnosis and disease management1. Previous epidemiological estimates of…
Abstract Number: 0214 • ACR Convergence 2025
Systematic Comorbidity Screening in Inflammatory Arthritis: The Experience of a Tertiary-Care Centre
Camille Bourgeois¹, Alexandra Kobza², Olivier Fogel³, Maxime Dougados⁴ and Anna Molto⁵, ¹Hospital general universitario Gregorio Marañon, Madrid, Madrid, Spain, ²University of Calgary, North Vancouver, BC, Canada, ³AP-HP, Paris, France, ⁴Department of Medicine, Hopital Cochin, Universite de Paris, Paris, France, ⁵Assistance Publique Hôpitauxde Paris, Paris, France
Background/Purpose: Patients with inflammatory arthritis (IA), including rheumatoid arthritis (RA) and spondyloarthritis (SpA), are at elevated risk for comorbidities, complicating disease management. Despite rheumatology societies…
Abstract Number: 2067 • ACR Convergence 2025
Patterns of Comorbidity in Idiopathic Inflammatory Myopathies: A Cross-sectional Analysis of Disease Burden and Risk Factors
Ilke Coskun Benlidayi¹, Meghna Lama², Oladipo Kunle Afolayan², Meera Shah³, Manali Sarkar⁴, Tamar Rubinstein⁵, Aleksandra Opinc-Rosiak⁶, Rada Miskovic⁷, Marcin Milchert⁸, Dimitri Luz Felipe da Silva⁹, Samuel Katsuyuki Shinjo¹⁰, Elena Nikiphorou¹¹, Ioannis Parodis¹², Vincenzo Venerito¹³, Vikas Agarwal¹⁴ and Latika Gupta¹⁵, ¹Cukurova University, Adana, Turkey, ²The University of Texas Health Science Centre at Houston School of Public Health: Houston, Texas, Houston, ³Indraprastha Apollo Hospital, New Delhi, Mumbai, Maharashtra, India, ⁴Sir H. N. Reliance Foundation Hospital and Research Centre, Mumbai, Maharashtra, India., Mumbai, Maharashtra, India, ⁵Albert Einstein College of Medicine, White Plains, NY, ⁶Medical University of Lodz, Zeromskiego ¹¹³, ⁹⁰-⁵⁴⁹ Lodz, Poland., Lodz, Poland, ⁷University of Belgrade; Clinic of Allergy and Immunology, University Clinical Centre of Serbia, Belgrade, Serbia, ⁸Pomeranian Medical University in Szczecin, Szczecin, Poland, ⁹University Santo Amaro, São Paulo, Brazil, Sao Paulo, Brazil, ¹⁰Faculdade de Medicina FMUSP, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, Sao Paulo, Brazil, ¹¹King's College London, London, United Kingdom, ¹²Karolinska Institutet and Karolinska University Hospital, Department of Medicine Solna, Division of Rheumatology, Stockholm, Sweden, ¹³Univeristy of Bari "Aldo Moro", Italy, Bari, Bari, Italy, ¹⁴Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India, ¹⁵School of Infection, Inflammation and Immunology, College of Medicine and Health, University of Birmingham; Royal Wolverhampton NHS Trust; Centre for Musculoskeletal Research, School of Biological Sciences, The University of Manchester, Manchester; Francis Crick Institute, London, Birmingham, UK, United Kingdom
Background/Purpose: Comorbidities contribute to the disease burden in idiopathic inflammatory myopathies (IIMs). Understanding their distribution and predictors across IIM subtypes can guide tailored strategies. This…
Abstract Number: 1381 • ACR Convergence 2025
Self-Reported and Actigraphic Sleep and Circadian Rhythm Disruptions in Patients with Sjögren’s Disease: Associations with Disease Activity and Patient-Reported Outcomes
Caterina Di Pede¹, Alessandro Colitta², Marco Di Galante³, Simone Bruno⁴, Stefano Donati¹, Beatrice Dei¹, Giovanni Fulvio¹, Gaetano La Rocca⁵, Rosaria Talarico⁶, Marta Mosca¹, Chiara Baldini⁷ and Ugo Faraguna⁴, ¹Rheumatology Unit, University of Pisa, Pisa, Toscana, Italy, ²Department of Translational Research and of New Surgical and Medical Technologies, University of Pisa, Pisa, Toscana, Italy, ³Sleepacta srl, Montacchiello, Pisa, Italy, Pisa, Toscana, Italy, ⁴Department of Translational Research and of New Surgical and Medical Technologies, University of Pisa., Pisa, Toscana, Italy, ⁵University of Pisa, Rheumatology Unit, Pisa, Pisa, Italy, ⁶Azienda Ospedaliero Universitaria Pisana, Pisa, Pisa, Italy, ⁷University of Pisa, Pisa, Pisa, Italy
Background/Purpose: Patients with Sjögren’s Disease (SjD) frequently report debilitating symptoms such as pain, fatigue, and dryness, significantly impacting health-related quality of life. Although sleep disturbances…
Abstract Number: 0200 • ACR Convergence 2025
Severe infections and malignancies in patients with cranial and extracranial giant cell arteritis treated with tocilizumab. National multicenter study of 471 patients of clinical practice
Adrian Martin-Gutierrez¹, Javier Loricera², Vicente Aldasoro Cáceres³, Olga Maiz⁴, Eugenio de Miguel⁵, Eva Galíndez Agirregoikoa⁶, Ivan Ferraz Amaro⁷, Santos Castañeda⁸ and Ricardo Blanco⁹, ¹Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain., Renedo de Piélagos, Spain, ²Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander , Spain, Santander, Spain, ³Hospital Universitario de Navarra, Pamplona, Spain, ⁴Hospital Universitario de Donosti, Donostia, Spain, ⁵Hospital Universitario La Paz, Madrid, Spain, ⁶BASURTO UNIVERSITY HOSPITAL, BILBAO, Spain, ⁷Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain, ⁸Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Madrid, Spain, ⁹Rheumatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain, Santander, Cantabria, Spain
Background/Purpose: Infections and malignancies are two of the most feared side effects of biologic therapies. Giant cell arteritis (GCA) is a vasculitis which affects older…
Abstract Number: 2065 • ACR Convergence 2025
Pain in Idiopathic Inflammatory Myopathies: A Global Study of Patient Experience
Lekshmi Minikumari Rahulan¹, Shounak Ghosh², Manali Sarkar³, Didem Saygin⁴, Karin Lodin⁵, Rima Shrestha⁶, Tulika Chatterjee⁷, Jessica Day⁸, Samuel Shinjo⁹, Sreoshy Saha¹⁰, Lorenzo Cavagna¹¹, Masataka Kuwana¹², Vikas Agarwal¹³ and Latika Gupta¹⁴, ¹Sanjay Gandhi Postgraduate Institute of Medical sciences Lucknow, Lucknow, Uttar Pradesh, India, ²Department of Rheumatology, The Royal Wolverhampton NHS Trust, Wolverhampton, UK, Wolverhampton, United Kingdom, ³Sir H. N. Reliance Foundation Hospital and Research Centre, Mumbai, Maharashtra, India., Mumbai, Maharashtra, India, ⁴Rush University Medical Center, Chicago, IL, ⁵Department of Gastro, Dermatology and Rheumatology, Karolinska University Hospital, Stockholm, Sweden, Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden, Stockholm, Sweden, ⁶Department of Internal Medicine, University of Illinois College of Medicine Peoria, Illinois, United States, Department of Research Services, University of Illinois College of Medicine Peoria, Illinois, United States, Illinois, ⁷Department of Internal Medicine, University of Illinois College of Medicine Peoria, Illinois, United States, Illinois, ⁸Walter and Eliza Hall Institute, Melbourne, Victoria, Australia, ⁹Division of Rheumatology, Faculdade de Medicina FMUSP, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, Sao Paulo, Brazil, ¹⁰Mymensingh Medical College, Mymensingh, Bangladesh, Mymensingh, Bangladesh, ¹¹Associate Professor in Rheumatology (Internal Medicine and Thepaeutics),University of Pavia, Pavia, Lombardy, Italy, Physician in Chief of Myositis Outpatients Clinic,Fondazione IRCCS Policlinico San Matteo, Pavia, Lombardia,Italy, Lombardia, Italy, ¹²Nippon Medical School Graduate School of Medicine, Tokyo, Japan, ¹³Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India, ¹⁴School of Infection, Inflammation and Immunology, College of Medicine and Health, University of Birmingham; Royal Wolverhampton NHS Trust; Centre for Musculoskeletal Research, School of Biological Sciences, The University of Manchester, Manchester; Francis Crick Institute, London, Birmingham, UK, United Kingdom
Background/Purpose: Pain remains a significant yet understudied aspect of idiopathic inflammatory myopathies (IIMs), considerably reducing quality of life despite advancements in immunomodulatory therapies. Information obtained…
Abstract Number: 1320 • ACR Convergence 2025
Trends In Incidence and Risk factors For Incident Venous Thromboembolism in Patients with Rheumatoid Arthritis: A Population-Based Retrospective Cohort Study
Noah Frechette¹, Elena myasoedova¹, Iqra Javed¹, Roslin George¹, Sara Achenbach² and Cynthia Crowson³, ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic, Rochester, ³Mayo Clinic, Stewartvillle, MN
Background/Purpose: Venous thromboembolism (VTE) is more common in patients with rheumatoid arthritis (RA) and can present as deep vein thrombosis (DVT) or pulmonary embolism (PE).…
Abstract Number: 0190 • ACR Convergence 2025
Health literacy and comorbidity burden: a cluster analysis in a national cohort of people with inflammatory arthritis
Mrinalini Dey¹, James Galloway², Andrew Cope², MAYA BUCH³, Richard Osborne⁴, Sam Norton² and Elena Nikiphorou², ¹Centre for Rheumatic Diseases, King's College London, London, United Kingdom, ²King's College London, London, United Kingdom, ³UNIVERSITY OF MANCHESTER, MANCHESTER, United Kingdom, ⁴La Trobe University, Melbourne, Victoria, Australia
Background/Purpose: Health literacy is a social determinant of health in people with chronic diseases, including inflammatory arthritis (IA). We aimed to assess the association between…
Abstract Number: 2682 • ACR Convergence 2025
Methotrexate use and higher age impair humoral response against the recombinant herpes zoster vaccine (RZV) in Rheumatoid Arthritis: a prospective, randomized, placebo-controlled trial
Ana C Medeiros-Ribeiro¹, Lucas Farias², Nadia Emi Aikawa³, Sandra G Pasoto¹, Leonard V Kupa², Carla Saad¹, Andrea Shimabuco², Karina Bonfiglioli⁴, Diogo Domiciano⁴, Andre Franco⁴, Clovis Artur Silva⁵ and Eloisa Bonfa⁶, ¹Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, Sao Paulo, Brazil, ²Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, São Paulo, Sao Paulo, Brazil, ³Rheumatology Division and Pediatric Rheumatology Unit, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, Sao Paulo, São Paulo, Brazil, ⁴Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, Sao Paulo, Sao Paulo, Brazil, ⁵University of São Paulo, São Paulo, São Paulo, Brazil, ⁶Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, São Paulo, Brazil
Background/Purpose: The recombinant vaccine against herpes zoster (HZ) (RZV) is recommended by ACR and EULAR for immunocompromised individuals. Short-term observational data from RA cohorts aged…
Abstract Number: 2038 • ACR Convergence 2025
Real-World Use of Dual Targeted Therapy in Rheumatic Disease: A Single-Center Case Series
Marta Aguilar Zamora¹, Karla Romelia Arévalo Ruales², marta Garijo Bufort², Maria Isabel Pastor Orduña¹, Celia Aparicio Rubio³, Silvia Cornejo Uixeda⁴ and Joaquín Borrás Blasco⁴, ¹Rheumatology Department, Hospital de Sagunto, Spain, Puerto de Sagunto, Comunidad Valenciana, Spain, ²Rheumatology Department, Hospital de Sagunto, Spain, valencia, Spain, ³Pharmacy Department, Hospital de Sagunto, Spain, Puerto de Sagunto, ⁴Pharmacy Department, Hospital de Sagunto, Spain, Puerto de Sagunto, Spain
Background/Purpose: Combination therapy with two biologic agents (bDMARDs) or a biologic plus a Janus kinase inhibitor (JAKi) is rarely used in rheumatology due to safety…
Abstract Number: 1316 • ACR Convergence 2025
Predicting mortality of rheumatoid arthritis in China: A nation-wide cohort study
Kangping Huang¹, Shixiong Wei², Lan Zhang³, Xinhao Li², Mucong Li², Chen Yu⁴, Nan Jiang², Jiuliang Zhao², Yanhong Wang⁵, Chanyuan Wu², Peng Yin⁶, Qian Wang², Mengtao Li², Xinping Tian² and Xiaofeng Zeng⁷, ¹Peking Union Medical College, Beijing, Beijing, China (People's Republic), ²Peking Union Medical College Hospital, Beijing, Beijing, China (People's Republic), ³School of Public Health, Peking University, Beijing, Beijing, China (People's Republic), ⁴Peking Union Medical College Hospital, Dong Cheng Qu, Beijing, China (People's Republic), ⁵Department of Epidemiology and Biostatistics, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences, School of Basic Medicine, Peking Union Medical College, Beijing, Beijing, China (People's Republic), ⁶National Center for Chronic and NCD Control and Prevention, Chinese Center for Disease Control and Prevention, Xicheng, Beijing, China (People's Republic), ⁷Peking Union Medical College Hospital Department of Rheumatology and Clinical Immunology, Beijing, Beijing, China (People's Republic)
Background/Purpose: Rheumatoid arthritis (RA) is a chronic autoimmune disease associated with increased mortality, primarily due to systemic inflammation and comorbidities. While previous studies have identified…
Abstract Number: 0169 • ACR Convergence 2025
The High Disease Burden of Connective Tissue Disorder-Interstitial Lung Disease in the USA Demonstrates an Unmet Need for Earlier Diagnosis and Treatment
Sally Wetten¹, George Mu², Keele E. Wurst³, Roger A. Levy⁴, Ben Newth⁵, Svetlana I. Nihtyanova⁶ and Elaine Irving⁷, ¹GSK, Epidemiology, Stevenage, United Kingdom, ²GSK, Statistics, Collegeville, PA, ³GSK, Immunology and Emerging Epidemiology, Durham, NC, ⁴GSK, Specialty Care, Global Medical Affairs, Collegeville, PA, ⁵GSK, Specialty Care, Global Medical Affairs, London, United Kingdom, ⁶GSK, Clinical Sciences, Research & Development, London, United Kingdom, ⁷GSK, Clinical, Stevenage, United Kingdom
Background/Purpose: Interstitial lung disease (ILD) is a serious pulmonary manifestation that can occur across all connective tissue disorders (CTD). Aberrant immune-mediated inflammation and fibrosis leads…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].